Ro 10-9359, an aromatic retinoid in the treatment of psoriatic arthritis. Clinical and immunological studies.
Clinical, general laboratory evaluation and immunological studies were conducted in 13 patients with active psoriatic arthropathy undergoing long-term treatment with aromatic retinoid (ethyl-all-trans-9-) (4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenate (Ro 10-9359). Evaluations were made at the beginning of treatment and at 3 and 6 months following drug therapy. A significant improvement in the clinical and laboratory parameters of inflammation was noted. In addition, immunological studies revealed certain changes suggesting that the treatment with Ro 10-9359 may effect some basic mechanisms of etiopathogenic significance in this disease. However, some undesirable, mostly dose-dependent adverse reactions affecting the muco-cutaneous tissues limit a wide use of this agent.
D000328:Adult; D001168:Arthritis / Q000188:drug therapy* / Q000276:immunology; D005050:Etretinate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D007136:Immunoglobulins / Q000096:biosynthesis; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D014212:Tretinoin / Q000031:analogs & derivatives*
D007136:Immunoglobulins; D014212:Tretinoin; D005050:Etretinate; D007052:Ibuprofen